iShares Biotechnology ETF (IBB)
Assets
$10.51B
iShares
Fee
0.46%
a year
Yield
0.2%
NA
Components
236
top 10: 52%
Performance
The fund's own total return, a year on average over the longer periods; volatility is the yearly standard deviation of its returns.
This year
+19.0%
1 year
+31.2%
3 years
+18.4%
5 years
+5.5%
10 years
+8.7%
Volatility 18.5% over one year, 17.6% over three; Sharpe ratio over three years 0.80.
Largest components
| GILDGilead Sciences Inc | 8.94% | Healthcare | |
| AMGNAmgen Inc | 8.32% | Healthcare | |
| VRTXVertex Pharmaceuticals Inc | 7.36% | Healthcare | |
| MRNAModerna Inc | 6.23% | Healthcare | |
| REGNRegeneron Pharmaceuticals Inc | 5.84% | Healthcare | |
| NTRANatera Inc | 3.72% | Healthcare | |
| ARGXargenx NV ADR | 3.36% | Healthcare | |
| ILMNIllumina Inc | 2.80% | Healthcare | |
| RVMDRevolution Medicines Inc | 2.65% | Healthcare | |
| BIIBBiogen Inc | 2.34% | Healthcare |
Sectors
Healthcare100.0%
Regions
North America92.8%
Europe Developed2.8%
United Kingdom1.5%
Asia Emerging0.2%
Australasia0.1%
Asia Developed0.0%
Asset classes
Stock US92.9%
Stock non-US5.2%
Cash0.1%
About the fund
- Issuer
- iShares
- Since
- 2001-02-05
- Listed on
- NASDAQ
- ISIN
- US4642875565
- Turnover
- 14% a year
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
From the market data provider's fund data, read 2026-10-19. Returns are the fund's own; past returns say nothing certain about future ones. None of this is advice.